Validated HS578T Xenograft Model:
Subcutaneous And Orthotopic Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

The Role of Xenografts in Advancing Breast Cancer Therapies

Breast cancer remains one of the most prevalent and devastating cancers worldwide, with an estimated one in eight women affected during their lifetime. It is characterized by uncontrolled cell growth in breast tissue, which can spread to other parts of the body if left untreated. Despite advances in early detection and treatment, metastasis and drug resistance continue to pose significant challenges. To overcome these hurdles, researchers have turned to innovative models like xenografts, which are crucial in cancer drug development. There are two primary types of xenograft models used in breast cancer research: patient-derived xenografts (PDXs) and cell line-derived xenografts (CDXs). PDX models involve the transplantation of primary human tumor tissue into immunocompromised mice, preserving the genetic and histological characteristics of the original tumor. This makes PDXs highly valuable for studying patient-specific tumor biology and personal treatment responses. On the other hand, CDX models use established human cancer cell lines implanted into animals, providing a more reproducible and standardized model for testing therapeutic agents.

HS578T Cell Line

HS578T cells are a human breast cancer cell line derived from the pleural effusion of a 44-year-old woman with metastatic breast cancer. This cell line is classified as triple-negative, meaning it does not express estrogen receptors (ER), progesterone receptors (PR), or the HER2 protein, characteristics that make it particularly relevant for studying aggressive forms of breast cancer. Due to their lack of these receptors, HS578T cells do not respond to conventional hormonal therapies, rendering them a crucial model for researching alternative treatment options. These cells are highly invasive and metastatic, providing a reliable platform for studying the mechanisms of tumor spread and the molecular processes underlying metastasis. Researchers utilize HS578T cells to explore drug resistance and identify potential therapeutic targets that can overcome the challenges presented by triple-negative breast cancer (TNBC). Additionally, they are used to evaluate the efficacy of novel therapies, including those aimed at inhibiting tumor progression or enhancing the body's immune response to cancer.



Figure 1. Tumor Histology. H&E stained slide of a subcutaneously-implanted HS578T tumor (Altogen Labs).

Altogen Labs Validated HS578T Xenograft Model

In preclinical xenograft studies at Altogen Labs, all HS578T cells are initially maintained at exponential growth levels to ensure they are in the optimal phase for collection. The cells are then harvested by trypsinization from the culture flasks, after which a cell count is conducted. Cell viability is assessed using trypan blue exclusion, ensuring a minimum of 98% viability before proceeding. The suspension is adjusted to the necessary density to match the required injection concentration. For the injection procedure, one million cells, suspended in a mixture of Matrigel and HS578T cells (100 µL), are injected subcutaneously into the rear flank of each mouse, which is either a NOD/SCID or athymic BALB/C mouse, aged between 10 to 12 weeks. The injection sites are carefully monitored until tumors are established, with tumor size being tracked using calipers once they reach an average size between 100-150 mm³.



Figure 2. HS578T breast cancer xenografted in immunocompromised mice, mean values +/- SEM (Altogen Labs).

Following randomization of the mice into treatment groups, the test compounds (or treatment articles) are administered according to a pre-established treatment schedule, as agreed upon by the study protocol. Tumor measurements are recorded daily, and the mice's weights are carefully monitored up to three times a week to assess general health and any treatment-related changes. When the tumors approach the upper size limit of 2,000 mm³ or the study's designated endpoint is reached, the animals are euthanized following established ethical guidelines. At the conclusion of the study, necropsies are performed, with tumors being removed, weighed, and documented using digital imaging technology. A selection of tissues predetermined by the study's protocol are collected through standard gross necropsy. These tissues are then processed by various methods, including snap freezing, submerging in RNAlater, nucleic acid isolation, or preparation for histological analysis, to further investigate the effects of the treatment.



Figure 3. Tumor weight of HS578T cells in control group mice and doxycycline treated mice at end of the study (Altogen Labs).

Exploring Tumor Growth and Response in Subcutaneous HS578T Models

The subcutaneous HS578T model involves the implantation of HS578T breast cancer cells into the flank of immunocompromised mice, where the tumors develop in a controlled, external environment. This model is commonly used to evaluate tumor growth, response to treatment, and the efficacy of novel therapeutic agents. While not representative of the natural microenvironment, the subcutaneous model provides a relatively simple and reproducible platform for studying the effects of drugs or treatments on tumor progression. Due to the high invasiveness of HS578T cells, subcutaneous tumors often grow rapidly, making them a valuable model for assessing the early stages of treatment response. This model is particularly useful for evaluating the potential of targeted therapies, including those aimed at blocking key signaling pathways involved in tumor growth and metastasis. Additionally, subcutaneous HS578T models can be employed to monitor immune responses to cancer therapies, including immunotherapies.

Orthotopic HS578T Xenograft Model

The orthotopic HS578T model involves implanting HS578T breast cancer cells directly into the mammary fat pad of immunocompromised mice, closely mimicking the natural tumor microenvironment and allowing for the study of tumor growth, metastasis, and therapeutic responses. This model is particularly valuable for investigating the progression of triple-negative breast cancer, as HS578T cells are known for their aggressive and metastatic properties. By growing and spreading in ways that resemble human breast cancer, the orthotopic model is ideal for evaluating the efficacy of novel therapies, including chemotherapies and targeted treatments. It also offers insights into drug resistance and immune response dynamics within the tumor microenvironment, making it essential for studying the interaction between tumor and immune cells. Furthermore, the orthotopic HS578T model allows for the exploration of metastatic behavior, providing critical information on the molecular mechanisms behind tumor spread to distant organs

Case Study: Exploring EMT Suppression in HS578T Cells

A study by Cai YJ, *et al.*, published by *Oncology Letters* journal, explored the tumor-suppressive role of Nischarin, an integrin-binding protein, in breast cancer, with a focus on its impact on epithelial-mesenchymal transition (EMT). Using the HS578T triple-negative breast cancer (TNBC) cell line, researchers found that Nischarin overexpression inhibits cancer cell migration and invasion. In contrast, silencing the NISCH gene in MDA-MB-231 cells led to increased cell proliferation, colony formation, and invasion. HS578T cells overexpressing Nischarin displayed higher levels of E-cadherin, a marker of epithelial integrity, while mesenchymal markers such as N-cadherin, vimentin, and transcription factors Snail, ZEB1, Slug, and Twist1 were downregulated. These changes indicate a suppression of EMT, a key process in cancer metastasis. Western blot and RT-qPCR analysis confirmed that Nischarin plays a critical role in regulating EMT-related transcription factors.

Additional Case Study: HS578T Driving Metastasis in Breast Cancer

In a study conducted by Kim, M., *et al*., published by *Scientific Reports* journal, researchers investigated the role of TrkC in metastatic breast cancer, and its ability to promote tumor progression and epithelial-mesenchymal transition (EMT). HS578T, a basal-like breast cancer cell line, was found to express high levels of TrkC, linking it to increased metastatic potential and tumor aggressiveness. The study revealed that TrkC stabilizes JAK2 by inhibiting SOCS3-mediated degradation, leading to the sustained activation of the JAK2/STAT3/Twist-1 axis. This pathway enhances mesenchymal characteristics in HS578T cells, reinforcing their invasive and metastatic behavior. Additionally, TrkC increases IL-6 secretion, forming an autocrine loop that maintains tumorigenicity and resistance to apoptosis. Knockdown of TrkC in HS578T cells significantly reduced their migratory and invasive capabilities, as well as tumor formation *in vivo*. These findings suggest that TrkC plays a crucial role in driving metastasis and may serve as a potential therapeutic target in aggressive breast cancers.

CNTN1 and Its Role in HS578T Breast Cancer Cell Growth and Metastasis

HS578T is a human triple-negative breast cancer (TNBC) cell line known for its aggressive phenotype, characterized by high proliferative capacity, invasion, and migration potential. Research has identified Contactin-1 (CNTN1) as a key regulator in these processes, with overexpression leading to enhanced tumor growth and metastatic capabilities. CNTN1 promotes cell cycle progression, increasing proliferation and colony formation *in vitro* while also driving tumor *expansion in vivo.* Additionally, its upregulation facilitates cell migration and invasion, suggesting a role in breast cancer metastasis. Targeting CNTN1 may offer a promising therapeutic approach for aggressive TNBC, as its inhibition has been linked to reduced tumor progression.

HS578T and PHGDH: Exploring Metabolic Vulnerabilities in Cancer

The HS578T human breast cancer cell line commonly used in oncology research, as they exhibit aggressive growth characteristics and lack estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, making them a valuable model for drug development targeting TNBC. HS578T cells have been shown to rely heavily on the serine synthesis pathway, with high expression of phosphoglycerate dehydrogenase (PHGDH), a key enzyme in this metabolic process. The regulation of PHGDH in HS578T cells is influenced by Parkin, an E3 ubiquitin ligase, which suppresses PHGDH activity through ubiquitination, thereby inhibiting serine synthesis and tumor proliferation. Studies indicate that PHGDH inhibition can significantly reduce the growth of HS578T-derived tumors, making it a potential therapeutic target. Furthermore, research suggests that the loss of Parkin in these cells contributes to metabolic vulnerabilities, highlighting the importance of targeting metabolic pathways in cancer therapy.

Immuno-oncology Xenograft Models

Altogen Labs specializes in immuno-oncology research using CD34+ humanized mice, a robust model for studying cancer immunotherapies. These immunodeficient mice, engrafted with CD34+ hematopoietic stem/progenitor cells (HSPCs), develop multi-lineage human immune cells, enabling long-term preclinical studies on therapies such as CAR-T cells and immune checkpoint inhibitors. Altogen Labs offers both custom and standardized humanized mouse models designed to replicate human immune responses, providing a reliable platform for assessing immuno-oncology treatments. Humanized immune system (HIoS) models, including Hu-CD34+ and Bone Marrow-Liver-Thymus (BLT) mice, closely mimic human immune-tumor interactions, making them essential for evaluating cancer therapies. The effectiveness of these models depends on the level of host immunodeficiency, with strains like NOD/SCID and NSG mice ensuring optimal engraftment and response to immunotherapies.



Figure 4. Advanced immune-oncology services available at Altogen Labs (Altogen Labs).

Altogen Labs offers an extensive range of options for the HS578T xenograft model, providing flexib ility to meet specific research needs. The model supports studies focused on tumor growth delay (TGD), tumor growth inhibition (TGI), and various dosing frequencies and durations. Researchers can select from a range of dosing routes, including intravenous, intraperitoneal, subcutaneous, intratumoral, oral gavage, and intranasal, with cutting-edge techniques such as micro-injection and pump-controlled IV injection. Other customizable options include alternative cell engraftment sites like orthotopic transplantation, tail vein injection for metastasis studies, and injections into the mammary fat pad or intraperitoneal cavity. The HS578T xenograft model also enables advanced analysis techniques like tumor immunohistochemistry, blood chemistry analysis, imaging studies (e.g., fluorescence-based whole-body imaging and MRI), and gross necropsies. With the ability to incorporate positive control groups, health observation programs, and toxicity/survival studies, this model offers a comprehensive platform for preclinical cancer research and therapy development.



Figure 5. Altogen Labs *in vivo* xenograft services for HS578T (Altogen Labs).

Altogen Labs also provides a wide array of preclinical research services, for the HS578T xenograft model that includes comprehensive tumor analysis capabilities, such as tumor immunohistochemistry, blood chemistry analysis, and imaging studies like fluorescence-based whole-body imaging and MRI, which provide detailed insights into tumor behavior and therapy response. Post-treatment studies can be further enhanced by performing gross necropsies, allowing for tissue collection and detailed histopathological analysis. Researchers can also monitor health status through a broad health observation program and assess toxicity and survival. With the flexibility to include positive control groups, such as treatments with doxorubicin or cyclophosphamide, Altogen Labs ensures that each study is robust and comprehensive. These diverse options make the HS578T xenograft model

Figure 6. Available *in vivo* toxicology services at Altogen Labs (Altogen Labs).

essential for preclinical research in the development of targeted therapies, drug resistance studies, and the exploration of metastasis in triple-negative breast cancer. Additionally, the HS578T xenograft model includes comprehensive tumor analysis capabilities, such as tumor immunohistochemistry, blood chemistry analysis, and imaging studies like fluorescence-based whole-body imaging and MRI, which provide detailed insights into tumor behavior and therapy response. Post-treatment studies can be further enhanced by performing gross necropsies, allowing for tissue collection and detailed histopathological analysis. Researchers can also monitor health status through a broad health observation program and assess toxicity and survival. With the flexibility to include positive control groups, such as treatments with doxorubicin or cyclophosphamide, Altogen Labs ensures that each study is robust and comprehensive. These diverse options make the HS578T xenograft model important for preclinical research in the development of targeted therapies, drug resistance studies, and the exploration of metastasis in triple-negative breast cancer.

References:

Cai YJ, Ma B, Wang ML, Chen J, Zhao FG, Zhou JD, Guo X, Zheng L, Xu CJ, Wang Y, He YB, Liu J, Xie SN. Impact of Nischarin on EMT regulators in breast cancer cell lines. *Oncol Lett.* 2020 Dec;20(6):291. doi: 10.3892/ol.2020.12154. Epub 2020 Sep 25. PMID: 33101485; PMCID: PMC7576990.

Chen, N., He, S., Geng, J. *et al.* Overexpression of Contactin 1 promotes growth, migration and invasion in Hs578T breast cancer cells. *BMC Cell Biol* 19, 5 (2018). https://doi.org/10.1186/s12860-018-0154-3

Conner SJ, Guarin JR, Le TT, Fatherree JP, Kelley C, Payne SL, Parker SR, Bloomer H, Zhang C, Salhany K, McGinn RA, Henrich E, Yui A, Srinivasan D, Borges H, Oudin MJ. Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential. *Breast Cancer Res*. 2024 Mar 11;26(1):43. doi: 10.1186/s13058-024-01796-8. PMID: 38468326; PMCID: PMC10929179.

Kim, M., Jeong, J., Seo, J. *et al.* Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer. *Sci Rep* 6, 33899 (2016). https://doi.org/10.1038/srep33899

Liu J, Zhang C, Wu H, Sun XX, Li Y, Huang S, Yue X, Lu SE, Shen Z, Su X, White E, Haffty BG, Hu W, Feng Z. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. *J Clin Invest*. 2020 Jun 1;130(6):3253-3269. doi: 10.1172/JCI132876. PMID: 32478681; PMCID: PMC7260041.

Witschen PM, Chaffee TS, Brady NJ, Huggins DN, Knutson TP, LaRue RS, Munro SA, Tiegs L, McCarthy JB, Nelson AC, Schwertfeger KL. Tumor Cell Associated Hyaluronan-CD44 Signaling Promotes Pro-Tumor Inflammation in Breast Cancer. *Cancers (Basel)*. 2020 May 22;12(5):1325. doi: 10.3390/cancers12051325. *Cancers (Basel)*. 2020 Sep 23;12(10):E2736. doi: 10.3390/cancers12102736. PMID: 32455980; PMCID: PMC7281239.

Keywords: HS578T, breast cancer, xenograft, breast, *in vivo*, cancer, preclinical, research, *in vivo* pharmacology, orthotopic, imuno-oncology, CDX, PDX

Other Available Altogen Labs Validated Xenograft Models:

A549 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/a549-xenograft-model/

Calu-3 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/calu-3-xenograft-model/

Cal-6 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/calu-6-xenograft-model/

NCI-H460 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h460-xenograft-model/

NCI-H1975 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/nci-h1975-xenograft-model/

NCI-H226 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/nci-h226-xenograft-model/

NCI-H1155 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h1155-xenograft-model/